贝达药业(300558.SZ)：MRX-2843属于一个具有探索性靶点的新药

Group 1 - The core point of the article is that BeiGene (300558.SZ) is currently conducting translational medicine exploratory research on its new drug MRX-2843, which targets an exploratory target and aims to identify precise patient populations for its indications [1] Group 2 - The company has stated that it will promptly disclose any significant progress related to the MRX-2843 project [1]